Celgene enters strategic collaboration with MedImmune for hematologic malignancies

Client(s) Celgene Corporation

Jones Day acted as special patent counsel, IP technology transaction counsel, and tax counsel on Celgene Corporation's strategic collaboration with MedImmune regarding human monoclonal antibody MEDI-4736 directed to PD-L1 to allow the immune system to continue to fight blood cancers. Under the terms of the agreement disclosed, Celgene paid $450 million in upfront fees, will lead clinical development and commercialization activities, and will receive royalties on sales.